5-12
Study of oral anti-diabetic therapy and effectiveness of such therapy on patients with type II Diabetes Mellitus of more than five years on treatment
Authors: P Madhav, B Kodandaramu, V Yamini, Munge Basawaraj, Bandopadhya Mamata
Number of views: 377
Diabetes Mellitus will eventually cause cardiac, vascular, renal, hematological, ocular, and neuronal complications and will result in end organ failure. FBS, PPBS and HbA1c are now the most important parameters for diagnosis and management of diabetes. In this study 150 patients with Diabetes Mellitus type II were enrolled from OPD’s of Medicine and Surgery departments, MIMS. After fulfilling the selection criteria, patients were categorized into four groups according to the treatment schedule. Group –1 were on tablet Metformin (500 -1000mg ), group – 2 were on tablet Glimepiride (1-4mg) group -3 were on combination of Metformin(500/1000mg) + Glimepiride (1-4mg) and group-4 with combination of Metformin (500/1000mg) + Glimepiride (1-4mg) + Pioglitazone (15-30mg). The efficacy variables taken in this study were percentage decrease in FBS, PPBS and HbA1c. There is no significant difference between group-1(Metformin) and group-2 (Glimepiride) in lowering FBS, PPBS and HbA1c. Metformin + Glimepiride and Metformin + Glimepiride + Pioglitazone, reduces the FBS, PPBS and HbA1c levels more when compared to the Metformin/Glimepiride. Most of the drugs fail to achieve the glycemic control. This emphasizes the fact that patient education and compliance of therapy is urgently needed to prevent or reduce the risk of developing the complications.